In Vivo Activity of Posaconazole against Mucor spp. in an Immunosuppressed-Mouse Model-Reference-Cited by-同舟云学术

In Vivo Activity of Posaconazole against Mucor spp. in an Immunosuppressed-Mouse Model

Published:2002-07 Issue:7 Volume:46 Page:2310-2312
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Sun Qiu N.¹²,Najvar Laura K.¹,Bocanegra Rosie¹,Loebenberg David³,Graybill John R.¹

Affiliation:

1. Division of Infectious Disease, Department of Medicine, The University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229-3900

2. Department of Dermatology, Beijing Union Medical University Hospital, Beijing, 100730 People's Republic of China

3. Schering-Plough Research Institute, Kenilworth, New Jersey 07033-1300

Abstract

ABSTRACT The in vivo activities of posaconazole, itraconazole, and amphotericin B in neutropenic mice with zygomycosis were compared. The in vitro MICs of posaconazole and itraconazole for the strains of Mucor spp. used in this study ranged from 0.125 to 8 μg/ml and 0.25 to 8 μg/ml, respectively. The in vitro MIC range for amphotericin B is 0.125 to 0.25 μg/ml. At twice-daily doses of ≥15 mg/kg of body weight, posaconazole prolonged the survival of the mice and reduced tissue burden.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.46.7.2310-2312.2002

Reference19 articles.

1. Comparison of In Vitro Activities of the New Triazole SCH56592 and the Echinocandins MK-0991 (L-743,872) and LY303366 against Opportunistic Filamentous and Dimorphic Fungi and Yeasts

2. Gomez-Lopez, A., M. Cuenca-Estrella, A. Monzon, and J. L. Rodriguez-Tudela. 2001. In vitro susceptibility of clinical isolates of Zygomycota to amphotericin B, flucytosine, itraconazole and voriconazole. J. Antimicrob. Chemother.48:919-921.

3. Gonzalez, C. E., D. R. Couriel, and T. J. Walsh. 1997. Disseminated zygomycosis in a neutropenic patient: successful treatment with amphotericin B lipid complex and granulocyte colony stimulating factor. Clin. Infect. Dis.24:192-196.

4. Graybill J. R. 1988. Zygomycosis and phaeohyphomycosis. In Current therapy in pediatric infectious diseases vol. 2. B. C. Deecker Inc. Philadelphia Pa.

5. Herbrecht, R., V. Letscher-Bru, R. A. Bowden, S. Kusne, E. J. Anaissie, J. R. Graybill, G. A. Noskin, B. A. Oppenheim, E. Andrès, and L. A. Pietrelli. 2001. Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersion. Eur. J. Clin. Microbiol. Infect. Dis.20:460-466.

Cited by 170 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mucormycosis: A hidden mystery of fungal infection, possible diagnosis, treatment and development of new therapeutic agents;European Journal of Medicinal Chemistry;2023-01

2. Effect of antifungal drugs against mucormycosis and impact on human health;Materials Today: Proceedings;2023

3. Mucormycosis;Diagnosis and Treatment of Fungal Infections;2023

4. Mucormycosis: The hidden and forgotten disease;Journal of Applied Microbiology;2022-06-01

5. Facial nerve palsy as an unusual presentation of orbital apex syndrome;Pediatria i Medycyna Rodzinna;2021-06-04